Baidu
map

CA-Cancer J Clin:**医学期刊CA发文-生存期可超过10年!手术为转移性软组织肉瘤患者带来生存获益

2019-01-09 肿瘤资讯编辑部 肿瘤资讯

近期,发布在Journal of Surgical Oncology杂志的一项回顾性研究显示,对于部分高选择性的转移性软组织肉瘤患者,对转移灶进行反复切除,可以延长患者的总生存期。国际顶级医学期刊CA对该文章发布点评,并进行了系统性介绍。

近期,发布在Journal of Surgical Oncology杂志的一项回顾性研究显示,对于部分高选择性的转移性软组织肉瘤患者,对转移灶进行反复切除,可以延长患者的总生存期(Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis.J Surg Oncol,2018,118: 167-176)国际顶级医学期刊CA对该文章发布点评,并进行了系统性介绍。

背景

该研究的共同作者,来自德国图宾根大学的Hans-Georg Kopp教授介绍道: “仅有少数回顾性研究显示,软组织肉瘤患者接受肺转移灶切除可以带来生存获益。我们这一研究并没有颠覆既往研究的结果,且进一步证实了既往的研究:对于肉瘤患者而言,转移灶切除可能带来获益,尤其是在部分经过高度选择的患者。如转移灶的可切除性、复发时间、转移灶数目等患者的临床特征是评估患者能否进行转移灶切除的重要指标。”

入组人群

该研究纳入了德国图宾根大学医院1982年10月至2015年10月期间诊断为肉瘤的患者,要求患者年龄为18岁或以上,接受过局部或远处转移灶的切除。主要研究终点为转移性肉瘤患者的总生存期。研究者纳入了一系列可能影响总生存期的指标,包括患者性别、诊断年龄、组织学类型和分级、解剖部位、原发灶切除情况、进行主要组织学诊断的医院、肿瘤转移时间、转移部位、转移灶数目、转移灶治疗情况(包括第一次发现转移灶时的切除情况、转移灶切除数目、每次手术时切除的转移灶数目、肺转移灶切除数目、肺转移灶切除所用的外科技术、肺转移灶切除类型)、疾病结局(包括在发生远处转移前是否出现局部复发,无进展生存间期PFI),以及一线治疗是单纯手术还是手术联合放疗、化疗或放化疗。

该研究共纳入102例患者(男性42例、女性60例),要求入组患者至少接受过一个转移灶切除;患者诊断时的年龄为19~85岁。入组人群的中位年龄为47岁。因为存放10年的病理标本已经常规丢弃,因此26例(25.5%)患者的中心病理评估无法进行。76例能够进行中心病理评估的患者,研究中心病理医生修改了其中9例患者的病理诊断,14例患者的组织学分级,3例患者的病理诊断和组织学分级。

主要研究结果

入组的102例患者中,研究者可以评估89例(87.3%)患者的组织学分级,其中37例转移性肉瘤患者的最初诊断为低级别(1~2级),52例患者为高级别。50例患者诊断时记录了原发肿瘤大小,其中4例患者的原发病灶<5cm,46例患者的原发病灶≥5cm。 

研究者发现24例患者在原发诊断时合并同时性转移,69例患者后续出现异时性转移。72例患者仅合并1个转移灶,30例患者有2个或以上转移灶。44例(43.1%)患者首次单个转移部位为肺。在首次观察到转移后,80例患者于当时进行了转移灶切除,22例患者后续进行了转移灶切除。53例患者接受过1次以上的转移灶切除,其中28例(27.5%)患者接受了2个转移灶切除;17例(16.7%)患者接受了3个转移灶切除;3例(2.9%)患者接受了4个转移灶切除;3例(2.9%)患者接受了5个转移灶切除;1例(0.1%)患者接受了7个转移灶切除。在合并肺转移的患者中,44例(43.1%)患者并未进行肺转移灶切除,因为他们的肺转移灶不可切除或其中1个或以上肺转移灶无法切除。

12例患者在出现远处转移之前先合并局部复发,90例患者仅表现为远处转移。96例患者的PFI可以评估,其中44例患者的PFI短于12个月,52例患者的PFI为12个月或以上。在中位观察118个月后,102例软组织肉瘤患者的中位总生存期为64个月;3年、5年、10年和20年的生存率分别为70.7%、50.3%、24.7%和14.8%。这些研究结果与既往报道相似,尤其是与法国肉瘤协作组报道的1024例合并同时性转移的软组织肉瘤患者研究结果一致 (Cancer,2011,117:1049-1054) 。 

研究优势和局限性

Kopp教授表示,尽管这一研究结果并没有出乎意料的惊喜,但研究仍有一定的优势,如研究样本量相对较大,且经过了较长时间的随访。总体而言,研究者认为,对于合并可切除病灶的患者,尤其是转移发生在较长PFI之后的患者,转移灶切除是一个有效的治疗选择,在发现转移灶时进行手术切除可以带来显著的生存获益;对于再次复发的患者也同样适用。值得一提的是,有很大比例的患者取得了至少10年的长期生存。

美国爱默里大学的Keith A. Delman教授评论道,这一研究具有很好的临床启示意义,因为对于大多数类型的转移性肉瘤患者,缺乏有效的系统性治疗手段,可考虑选择手术治疗。对于适合手术的患者,手术仍然是主要治疗选择,即使是创伤性较大的手术。 

Kopp教授认为,接下来应该进一步深入探索这类患者的分子病理特征,如了解不同亚型软组织肉瘤患者是否合并特定类型的突变,可以建议进行有效的靶向治疗,而非单纯地进行手术切除。 

原始出处:

Mike Fillon. Surgery remains the best solution for patients with soft‐tissue sarcomas. CA: A Cancer Journal for Clinicians. Nov 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-11 qilu_qi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1780522, encodeId=15251e8052244, content=<a href='/topic/show?id=dbc6392906' target=_blank style='color:#2F92EE;'>#CA-Cancer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3929, encryptionId=dbc6392906, topicName=CA-Cancer)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Tue Jul 09 06:50:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006940, encodeId=5e932006940c2, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Sat Jan 12 07:50:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378202, encodeId=201d13e82028c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386461, encodeId=cabc1386461e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420429, encodeId=1c61142042974, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513911, encodeId=e2901513911ba, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Fri Jan 11 13:50:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357694, encodeId=4fea35e694de, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jan 09 23:26:15 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-09 天地飞扬

    了解一下,谢谢分享!

    0

Baidu
map
Baidu
map
Baidu
map